What is Cogent Biosciences, Inc.'s market cap?

Cogent Biosciences, Inc. (COGT) has a market capitalization of $7.2B and trades on NASDAQ.

Who are Cogent Biosciences, Inc.'s competitors?

Cogent Biosciences, Inc.'s key competitors include Incyte, Pfizer Inc., Amgen Inc., and others. These companies compete in similar markets and product categories.

Who does Cogent Biosciences, Inc. partner with?

Cogent Biosciences, Inc.'s notable partners include Plexxikon Inc., Daiichi Sankyo, Sarcoma Alliance for Research through Collaboration, and others.

What subsidiaries does Cogent Biosciences, Inc. have?

Cogent Biosciences, Inc.'s subsidiaries include Kiq Bio LLC.

Where is Cogent Biosciences, Inc. headquartered?

Cogent Biosciences, Inc. is headquartered in United States of America and employs approximately 164 people. It has been publicly traded since 2018.

Cogent Biosciences (COGT) Stock Fundamentals & Financials

Cogent Biosciences is a clinical-stage biotechnology company specializing in the development of precision therapies for genetically defined diseases.

Market cap

$7.22B+371%

Net income-$354.3M-31.5%

Free cash flow-$286.3M-28.5%

EPS (diluted)-$2.17-10.2%

Trailing twelve months · change vs. prior year

Earnings

Q1 2026 report

May 5, 2026

EPS-$0.53In line

Read the full report

Next report

Aug 10, 2026 (In 3 days)

Revenue estimate$1.0K

EPS estimate-$0.55

Financials

Q1 2026

Income statement

See full

Operating income-$103.6M-38.3%

Net income-$97.4M-35.2%

EPS (diluted)-$0.53-1.9%

Balance sheet

See full

Cash & equivalents$241.2M+91.4%

Total debt$15.5M-9.4%

Total equity$607.7M+177%

Total assets$903.0M+218%

Cash flow

See full

Operating cash flow-$86.9M-30.6%

CapEx$449.0K-17.9%

Free cash flow-$87.3M-30.2%

Valuation & ratios

Valuation

See full

Market cap$7.22B+371%

Enterprise value$7B+377%

Returns & leverage

See full

Return on equity-85.7%+1.7pp

Debt / equity0×-0.1×

Current ratio15.1×+10.0×

Competitors

By market cap

Amgen$220.64B+44.0%

Pfizer$147.11B+8.1%

Incyte$24.3B+60.1%

Cogent Biosciences, Inc.$7.2B+371%

Tango Therapeutics$4.7B+565%

Arcus Biosciences$3.5B+247%

CytomX Therapeutics$729.3M+113%

Mustang Bio$4.5M-29.7%

By revenue growth

Tango Therapeutics+39.0%

Incyte+26.9%

Amgen+9.1%

Pfizer-0.2%

Arcus Biosciences-55.3%

CytomX Therapeutics-87.0%

By net margin

Incyte27.71%+8.7pp

Amgen22.95%+4.0pp

Pfizer15.65%+1.6pp

Tango Therapeutics-188.15%+135pp

Arcus Biosciences-393.16%-279pp

CytomX Therapeutics-435.21%-469pp

Cogent Biosciences, Inc.-950.43%—

Profile

Cogent Biosciences is a clinical-stage biotechnology company specializing in the development of precision therapies for genetically defined diseases. The company focuses on designing rational small molecule inhibitors that target the underlying causes of rare diseases and cancers, with a primary emphasis on KIT-driven mutations.

Competitive position

Clinical-stage developer with positive registrational trial data for its lead candidate, bezuclastinib, aiming for commercial launch in the second half of 2026.

GeographiesUnited States, European Union, United Kingdom

Customer segmentsRare Disease Patients, Oncology Patients

Business modelResearch and Development, Intellectual Property Licensing

SuppliersThird-party contract manufacturing organizations (CMOs), Academic research institutions, Clinical trial sites, Specialized chemical suppliers

CustomersSpecialty pharmacies, Hospitals, Oncology clinics, Government and private healthcare payors

CountryUnited States of America

Listed2018

Employees164.0

CEOAndrew R. Robbins

SectorHealthcare

IndustryBiotechnology

Websitecogentbio.com

FilingsSEC EDGAR

FAQ

What is Cogent Biosciences, Inc.'s market cap?: Cogent Biosciences, Inc. (COGT) has a market capitalization of $7.2B and trades on NASDAQ.
Who are Cogent Biosciences, Inc.'s competitors?: Cogent Biosciences, Inc.'s key competitors include Incyte, Pfizer Inc., Amgen Inc., and others. These companies compete in similar markets and product categories.
Who does Cogent Biosciences, Inc. partner with?: Cogent Biosciences, Inc.'s notable partners include Plexxikon Inc., Daiichi Sankyo, Sarcoma Alliance for Research through Collaboration, and others.
What subsidiaries does Cogent Biosciences, Inc. have?: Cogent Biosciences, Inc.'s subsidiaries include Kiq Bio LLC.
Where is Cogent Biosciences, Inc. headquartered?: Cogent Biosciences, Inc. is headquartered in United States of America and employs approximately 164 people. It has been publicly traded since 2018.